tradingkey.logo

Apellis Pharmaceuticals Inc <APLS.OQ> expected to post a loss of 35 cents a share - Earnings Preview

ReutersMay 5, 2025 12:50 PM
  • Apellis Pharmaceuticals Inc APLS.OQ APLS.O is expected to show a rise in quarterly revenue when it reports results on May 7 for the period ending March 31 2025

  • The Waltham Massachusetts-based company is expected to report a 14.0% increase in revenue to $196.485 million from $172.33 million a year ago, according to the mean estimate from 21 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Apellis Pharmaceuticals Inc is for a loss of 35 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy," 8 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts had fallen by about 0.7% in the last three months. ​

  • Wall Street's median 12-month price target for Apellis Pharmaceuticals Inc is $41.50​, above​ its last closing price of $20.34. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.39

-0.39

-0.29

Beat

24.8

Sep. 30 2024

-0.30

-0.30

-0.46

Missed

-53.3

Jun. 30 2024

-0.30

-0.32

-0.28

Beat

13.5​

Mar. 31 2024

-0.50

-0.47

-0.42

Beat

10

​​Dec. 31 2023

-0.67

-0.69

-0.73

Missed

-6.4

Sep. 30 2023

-0.80

-0.86

-1.17

Missed

-36.8​

Jun. 30 2023

-1.32

-1.32

-1.02

Beat

22.9

Mar. 31 2023

-1.50

-1.46

-1.56

Missed

-6.5

This summary was machine generated May 5 at 12:50 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI